secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015569
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q2 net loss $37.1M; cash $177.6M, extended runway into H2 2025 via $130M private placement
--------------------------------------------------------------------------------

- Net loss of $37.1M ($0.96/share) vs. $31.3M ($0.82/share) in Q2 2021.
- Cash and short-term investments $177.6M at June 30, 2022, plus $130M from July private placement.
- Operating runway extended into second half of 2025.
- FDA granted Fast Track designation to ANX007 for geographic atrophy; Phase 2 enrolled.
- Phase 1 trials initiated for oral small molecule ANX1502 and next-gen mAb ANX105.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017022015569/0000950170-22-015569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017022015569/annx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer